Discovering next generation antibody-based therapeutics addressing challenging targets for the treatment of cancer.

Our Company

QLSF Biotherapeutics is an innovative immuno-oncology startup company in South San Francisco. Our research and development are focused on a diversified oncology portfolio, with strong financial and clinical development support from a leading pharmaceutical company.

Fully integrated research and development leveraging our interdisciplinary expertise

Our Approach

Rational design to build modular and customizable molecules

Our Science

Tumor biology driven therapeutic strategy and target selection

Our candidates are designed to target both the adaptive and innate immune systems, with complementary mechanisms of action for broad anti-tumor activity.

Myeloid Rich

Biology: Abundant myeloid cells in tumor

Strategy:
Tumor cell phagocytosis and antigen presentation

Candidates:

Immunologically Cold

Biology: T cells absent in tumor or periphery

Strategy:
Redirect and activate T cells

Candidates:

Next Generation T Cell Engagers

Inflamed​

Biology: Abundant T cells in tumor but inactive or exhausted

Strategy: Reactivate and invigorate T cells

Candidates:

Management

Shihao Chen, PhD
CEO, Co-Founder

Hieu Tran, MS
Co-Founder

Greg Naeve, PhD
Chief Business Officer

Advisors

Alan Wahl, PhD
Chief Scientific Advisor

Premal Patel, MD, PhD
Chief Medical Advisor

Pamela Garzone, PhD

News

June, 2024

QLSF’s China partner Qilu Pharmaceutical to present Phase 1 interim results of QL325 CLEC12A x CD3 at the EHA 2024 in Madrid.

June, 2024

QLSF’s China partner Qilu Pharmaceutical to present Phase 1 results of QL301 PD-L1 x 4-1BB at the ASCO Meeting 2024 in Chicago.

November 16, 2023

QLSF will present preclinical data of two new clinical stage programs at the AACR Annual Meeting 2024 in San Diego.

Poster presentations will include QL325, a novel T cell engager targeting CLEC12A for acute myeloid leukemia, and QL335, a novel T cell engager targeting LY6G6D for colorectal cancer. Both programs are currently in Phase 1 trial.

October 10, 2023

QLSF announces first patient dosed in a Phase 1 trial of QL335, a novel T cell engager targeting LY6G6D for colorectal cancer.

March 1, 2023

QLSF announces first patient dosed in a Phase 1 trial of QL325, a novel T cell engager targeting CLEC12A for acute myeloid leukemia.

November 20, 2021

QLSF Biotherapeutics to present preclinical data of 3 clinical stage programs at the AACR Annual Meeting 2022 in New Orleans.

Poster presentations will feature QL301 PD-L1 x 4-1BB bispecific antibody, QL401 PD-L1 x 4-1BB bispecific antibody, and QL415 PD-L1 IL-15 cytokine fusion protein.

November 2, 2021

First patient dosed in a Phase 1 study of QL415 PD-L1 x IL-15 cytokine fusion protein

The phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of QL415 as a monotherapy in patient with advanced malignant tumors.

October 21, 2021

First patient dosed in a Phase 1 study of QL301 PD-L1 x 4-1BB bispecific antibody

The phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of QL301 as a monotherapy in patient with advanced malignant tumors.